Yeah there's just nothing out there that is actually "substantive" though, for the masses, I suppose. And missing TLD just casts enough doubt for the "wait and see" attitude and risk calculations pending FLD and more "substance" on Nov 16, Nov 18, Dec 6 ... but, the Nov 13 meeting with the FDA, and news of what comes from that meetting is gonna be HUGE also for share price, potentially.

But ... Even with excellent FLD, if we need to go back and do another study, or even a bolt-on, it could still significanlty subdue confidence for pps because we are still not out of the anbiguous "study zone" and qctually ever getting to a panel review which still has its own uncertainties ... just speculating and jmho

... and of course, potential partnership/buyer news?

There are huge inflection points coming that are wayyyyy more potentially inspiring to investors than Don's "cloaked" enthusiasm re data data data ... although it was VERY encouraging, not saying it was "smoke & mirrors" ... it was VERY motivating, and I believe him that good things are coming, just not substantive yet.

BUT ... Even with great FLD for the triad of Cardio/Renal/Cognitive data I am still a bit skeptical about a BIG jump until there is clarity with the FDA pathway, and/or future "partner/buyer" news.

JMHO though